People · Operator

NEIL BODICK

Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Pharmaceuticals

2
Companies
5
Filings
$42.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Flexion Therapeutics IncBiotechnologySeries B$40.0M$793.8M2009
Gate Science Inc.PharmaceuticalsSeed$2.6M$1.7M2020
Operator network

NEIL BODICK at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Andrew Schwab · 16 companies · 1 sharedAndrew SchwabBRADLEY BOLZON · 10 companies · 1 sharedBRADLEY BOLZONHeath Lukatch · 10 companies · 1 sharedHeath LukatchElaine Jones · 6 companies · 1 sharedElaine JonesSAMUEL COLELLA · 3 companies · 1 sharedSAMUEL COLELLAAlan Milinazzo · 2 companies · 1 sharedAlan MilinazzoArthur Fratamico · 2 companies · 1 sharedArthur FratamicoMICHAEL CLAYMAN · 2 companies · 1 sharedMICHAEL CLAYMANPatrick Mahaffy · 1 companies · 1 sharedPatrick MahaffyRAFAELE TORDJMAN · 1 companies · 1 sharedRAFAELE TORDJMANLara Wynne · 1 companies · 1 sharedLara WynnePhillip Reilly · 1 companies · 1 sharedPhillip ReillySanjay Sinha · 1 companies · 1 sharedSanjay SinhaWilliam Suter · 1 companies · 1 sharedWilliam SuterFlexion Therapeutics Inc · $40.0M raisedFlexion Therapeutics …Gate Science Inc. · $2.6M raisedGate Science Inc.NEIL BODICKNB
NEIL BODICK Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside NEIL BODICK on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Andrew Schwab116
Heath Lukatch110
BRADLEY BOLZON110
Elaine Jones16
SAMUEL COLELLA13
Alan Milinazzo12
Arthur Fratamico12
MICHAEL CLAYMAN12
Patrick Mahaffy11
RAFAELE TORDJMAN11
William Suter11
Lara Wynne11
Phillip Reilly11
Sanjay Sinha11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.